This is all the other psychedelic research that came out in June 2021. These papers don’t (yet) have their own page in our database.

Find our recap of the most interesting papers this month in our June Recap.

You can find all interesting papers in our Papers Database.

Related papers

Use CTRL/CMD+F to quickly search if anything relevant for you has been published this month.

• Genetic deletion of β-arrestin 2 modulates LSD-stimulated behaviors in mice (in mice, finds that BArr2 seems to be needed for subjective LSD effects)
• Toxicology of Psychoactive Substances (review)
• Ayahuasca: What Healthcare Providers Need to Know (information for nurses)
• Psilocybin: A brief overview for psychiatric mental health nurse practitioners (information for nurses)
• Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications (review of novel compounds including psychedelics)
• Magnesium in Ketamine Administration in Treatment-Resistant Depression (“No significant correlation was observed between changes in magnesium serum levels and MADRS or YMRS.“)
• Immunoregulation and antidepressant effect of ketamine (review)
• Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics (musings on neurotoxicity of NPS, but inconclusive at the moment)
• Combining Ketamine and Internet-Based Cognitive Behavioural Therapy for the Treatment of Post-Traumatic Stress Disorder: Protocol for a Randomized Control Trial (protocol)
• Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies (commentary, need for more diverse research participants)
• A “Trip” to the Intensive Care Unit: An Intravenous Injection of Psilocybin (not available yet, could be about a widely reported case of IV injection of psilocybin)
• Microdosing LSD: practices and risks (French, pros and cons of microdosing)
• Psychedelic medicalization, public discourse, and the morality of ego dissolution (how politics, morality, and psychedelics intertwine)
• Consciousness is supported by near-critical cortical electrodynamics (pre-print, uses psychedelic state (amongst others) to infer that consciousness happens at the criticality level between chaos and order)
• Nicotine and Modafinil Combination Protects against the Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine in Hippocampal Neurons of Male Rats (in rats)
• Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment (editorial mostly about Williams et al., 2020)
• Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm (review, also with Australian policy in mind)
• Psychedelic-Assisted Psychotherapy and Carl Jung’s Red Book (historic viewpoint)
• Pharmahuasca Reduces ROS Production and inflammatory Gene Expression in the Brain in a Model of PTSD: Exploration by RNA Sequencing (pre-print, in mice)
• The structural simplification of lysergic acid as a natural lead for synthesizing novel anti-Alzheimer agents (lysergic acid (closely related to LSD) variations are found, in cells, to be more neuroprotective than the current best Alzheimers medication)
• Subcutaneous Ketamine in Depression: A Systematic Review (review, finds favorable results from subcutaneous (under the skin) ketamine trials)
• Changes in Online Psychoactive Substance Trade via Telegram during the COVID-19 Pandemic (changes in drug use (based on telegram messages) in The Netherlands during covid)
• Novel and atypical pathways for serotonin signaling (more on serotonin, not specifically related to psychedelics)
• Advances in the pharmacotherapeutic management of post-traumatic stress disorder (overview of new ways of treating PTSD)
• Perspectives for Therapy of Treatment-resistant Depression (overview of how to treat depression (TRD) with mention of ketamine and regulatory framework)
• Comparative Analysis of Pathobiochemical Changes in Major Depression and Post-Traumatic Stress Disorder (showing how (according to the authors) PTSD and depression are two opposite, but both maladaptative, reactions to stressors)
• Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse (expert opinion, ibogaine for SUD, positive about potential but also highlights current unsafe practices)
• Neural Dynamics in Primate Cortex During Exposure to Subanesthetic Concentrations of Nitrous Oxide (in monkeys, study of N2O in the brain)
• Where ketamine and dopamine collide (editorial, makes the connection between ketamine and production & regulation of dopamine)
• Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression? (investigating with which functional impairments people come into treatment and can best get out again)
• Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology (review of ketamine for depression)
• A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings (review, investigating the habenula as a place of interest in the brain and ketamine’s effects)
• Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects (combining CBD with ketamine for fewer adverse events)
• Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders (review, mostly based on animal studies with ketamine-like compounds)
• How do serotonergic psychedelics treat depression: The potential role of neuroplasticity (review)
• Neuroscience literacy and substance use prevention: How well do young people understand their brain? (discussion on video program for young adults regarding info on MDMA, alcohol, and cannabis and their brain)
• Psychedelics: A New Treatment Paradigm in Psychiatry? (commentary)
• Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy (biomarkers of ECT and ketamine treatment for TRD)
• Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review (review, points towards ketamine reducing inflammation)
• Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study (review and study that compares recreational and clinical ketamine use, the former being 90 times higher than the latter)
• Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders (review)
• “It Kind of Polishes All Your Flaws Away”: Long-term Experiences With Psilocybin Mushrooms and the Influence of Set and Setting (thesis)
• Adjunct pharmacotherapy for psychotherapy (review, d-cycloserine, intranasal oxytocin, propanolol, and psychedelics in combination with therapy, Matthew Johnson last author)
• Ketamine decreases HPA axis reactivity to a novel stressor in male but not female mice (in mice, pre-print, “Corticosterone levels in all mice correlated with immobility in the FST, suggesting that shared neural circuitry could mediate both endocrine and behavioral responses. This circuitry may be ketamine-responsive only in males.“)
• Human CYP2D6 in the Brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized CYP2D6 Transgenic Mice (in mice, again more info in CYP2D6 and neuroprotective effects, now against harmine neurotoxicity, harmine being part of an ayahauasca brew)
• Methylenedioxymethamphetamine (MDMA)-Induced Hyponatremia: Case Report and Literature Review (case report and review, recreational use of MDMA and its dangers)
• Psychedelic Assisted Therapy for Major Depressive Disorder: A Review (pre-print, review)
• Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature (review, ketamine for OCD which is also linked to SUD and ED as they share similar characteristics)
• Increased Entropic Brain Dynamics during DeepDream-Induced Altered Perceptual Phenomenology (using an algorithm to make videos that our brains react to as if in a psychedelic state)
• Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances (in cells, studies toxicity of novel compounds)
• Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine (information for pharmacists about ketamine for depression (TRD))
• Stroke and Adverse Effects on The Immune and Cardiovascular Systems: The Danger of the Rise and Use of Psychedelic Drugs for Depression and PTSD (short review about potential dangers of psychedelics, not too charitable)